The funding is for a joint program to develop diagnostic devices for preeclampsia with Canada's Miraculins.
High-risk pregnancy diagnostic solutions developer Diagostic Technologies Ltd. has obtained $782,000 from the Canada-Israel Industrial Research and Development Foundation (CIIRDF). The funding is for a joint project with Canadian diagnostic devices developer Miraculins Inc. (TSX: MOM) to develop diagnostic devices for preeclampsia.
Diagostic Technologies monitors high-risk pregnancies with biomarkers.
Published by Globes [online], Israel business news - www.globes-online.com - on May 24, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009